Arena Pharmaceuticals (NASDAQ:ARNA) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 2.5 by 6 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold. A sell rating was given by 1 analyst.
Arena Pharmaceuticals (NASDAQ:ARNA) shares are expected to touch $3 in the short term. This short term price target has been shared by 3 analysts. However, the standard deviation of short term price estimate has been valued at 1.32. The target price could hit $4 on the higher end and $2 on the lower end.
Arena Pharmaceuticals (NASDAQ:ARNA) witnessed a decline in the market cap on Tuesday as its shares dropped 1.58% or 0.03 points. After the session commenced at $1.9, the stock reached the higher end at $1.94 while it hit a low of $1.83. With the volume soaring to 885,967 shares, the last trade was called at $1.87. The company has a 52-week high of $5.12. The company has a market cap of $454 million and there are 243,044,670 shares in outstanding. The 52-week low of the share price is $1.3.
Arena Pharmaceuticals, Inc. has dropped 4.59% in the last five trading days, however, the shares have posted positive gains of 19.11% in the last 4 weeks. Arena Pharmaceuticals, Inc. has dropped 3.61% during the last 3-month period . Year-to-Date the stock performance stands at -1.58%.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.